Partnering with NORGANOID to Expand Cryopreservation Capabilities to Organoids
Coventry, UK – 02/09/2024 – NORGANOID, a biotech company that specializes in developing advanced human organoid systems for use in medical research and drug development announced a new research collaboration with CryoLogyx. This collaboration aims to extend CryoLogyx’s cryopreservation technologies to the field of organoids, enhancing their preservation, storage, and transportation. NORGANOID‘s advanced Nano Lab System, an AI-enabled platform that uses a patented fluidic approach to engineer complex human tissues, will play a crucial role in providing high-quality organoids for these preservation techniques.
"We are excited to partner with CryoLogyx to combine their cutting-edge cryopreservation technology with our invention. By enhancing the quality and availability of human organoids, this partnership will play a key role in advancing patient-focused drug research, enabling the development of more precise and efficient therapies tailored to individual needs."
— Charlotte Ohonin, CEO of NORGANOID
Organoids, complex, three-dimensional cell cultures derived from stem cells or patient cells that mimic key functions of human organs, are driving innovation in drug discovery, personalized medicine, and regenerative therapies. However, preserving these complex structures for long-term storage has been significantly challenging. CryoLogyx and NORGANOID are collaborating to overcome these challenges by developing specialized cryopreservation protocols designed to maintain the structural integrity, viability, and specific functional properties of organoids after thawing.
"Advancing the preservation and integration of viable cells is crucial for the success of cell therapies. The combination of NORGANOID’s advanced organoid platforms and our cryopreservation expertise will enable us to make organoid-based therapies more accessible and flexible. This collaboration is a promising step toward creating 'ready-to-use' organoid models that could significantly reduce costs and time in developing treatments.”
— Dr. Tom Congdon, CEO of CryoLogyx
The initial focus of the partnership will be on developing cryopreservation protocols for liver organoids. Liver organoids are particularly prioritized due to their critical role in drug metabolism and toxicity testing, making them invaluable in the early stages of drug development. Rigorous testing will be conducted to optimize the protocols, ensuring that organoids remain viable and functional after thawing. This initiative is expected to accelerate the adoption of organoids in both research and therapeutic contexts, making them more accessible and practical for a wide range of applications.
About CryoLogyx
CryoLogyx, founded in 2021 as a spin-out from the University of Warwick and based in Coventry, is an early-stage biotechnology company specializing in the development and production of frozen, ready-to-use cells for the medicine discovery, diagnostics, and cell therapy industries. CryoLogyx’s patented formulation, CryoShield™, is redefining the freezing, storage, and transportation of cells, ensuring that viable cells and cell therapies are delivered in user’s preferred format, ready for immediate use.
Website: www.cryologyx.com
Contact: info@cryologyx.com
LinkedIn: CryoLogyx
Twitter/X: CryoLogyx
About NORGANOID
NORGANOID GmbH, founded in 2022 and located in the Medical Science City of Graz, Austria, is a pioneering biotechnology company focused on developing its proprietary NanoLab System. This sophisticated platform engineers complex, high-quality organoids that closely mimic human tissues, transforming the way researchers and pharmaceutical companies approach drug discovery and personalized medicine.
Website: www.norganoid.com
Contact: office@norganoid.com
LinkedIn: NORGANOID GmbH
Twitter/X: norganoid